Stocks-VIR-Vir Biotechnology Inc

VIR Vir Biotechnology Inc

30.85 0.86 (2.87%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest
Invest
15.02% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
4.11B
Day’s Range
29.85
-
31.48
52W Range
18.03
-
35.38
Volume (3M)
843.15K
Price-Earnings Ratio
3.63
Revenue
2.38B

Vir Biotechnology Inc Latest News

View All
Pinned Post
eToro Team
🎉 Here’s a little preview introducing 16 YEARS of INVESTING on eToro 😏🤑 With love, - The eToro Team youtu.be/UFYvpJxh2qA
Like CommentShare
Show more comments2 of 52
5 replies
1 reply
null
.
Top Discussions
Nikolaos Zervos
There is an interesting survey titled: “AAII sentiment survey” that gives us the investors’ expectations about where the market is heading. This report has a 6 months forecasting outlook. Investors in the latest report seem to have turned more neutral and bearish compared to the previous report. Most... Show More
Nikolaos Zervos
Market analysis: We welcomed the good GDP numbers for the US Economy. GDP rose 2.9% in the forth quarter, beating the expectations and leaving a bullish sign for the economy. However the picture is still mixed. For starters, we have very tight labour supply. This means that there is more demand than... Show More
Like CommentShare
null
.
Justin Crowhurst
The Magic Formula stocks should outperform the general stock market. What is it? Does it still work today? Our free review & analysis.. Seems to be mixed opinions on the effectiveness of it over the last few years. moneysandi.com/beating-the-market-with-the-magic-formula-investing-strategy/ Generated... Show More
Bjorn Crienen
A well needed break. Hello everyone! As you can I see by the title of the post I am planning to take a sizeable break. I will however keep researching and adding stocks that seem fit for our portfolio. Copiers are unaffected by this change and can/ are more than welcome to ask questions and ask for... Show More
Like CommentShare
Show more comments2 of 6
1 reply
null
.
david bumpstead
𝙋𝙀𝙍𝙁𝙊𝙍𝙈𝘼𝙉𝘾𝙀 𝙍𝙀𝙑𝙄𝙀𝙒 - 𝙌𝟰 & 𝙁𝙔 𝟮𝟬𝟮𝟮 Dear Copiers and Followers, As we conclude Q4 and the full year of 2022 we will be taking a deeper dive into our portfolio's performance compared to the usual weekly and monthly reviews. This quarterly review is broken down into 3 components: -... Show More

About Vir Biotechnology Inc

Founded in 2016, Vir Biotechnology is a clinical-stage immunology company. It works to develop therapeutic products designed to treat and prevent a range of serious infectious diseases. Operating internationally, the company has headquarters in San Francisco, California. It is listed on the NASDAQ GS stock market with the VIR ticker. Add this stock to your eToro watchlist to follow VIR share price movements.
444
Employees
San Francisco, California, US
HQ
2016
Founded
George A. Scangos, PhD
CEO
Show More

Upcoming Earnings

23
FEB
REPORTS
Vir Biotechnology Inc Q4 2022 earnings report is expected to be released after market open

ESG: A New Source of Insight

Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
43
Low
Industry 
Avg. 45 
36
Environment
37
Social
53
Governance

People Also Bought